Rallybio (RLYB)
(Real Time Quote from BATS)
$1.03 USD
+0.01 (0.98%)
Updated Nov 6, 2024 10:42 AM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
RLYB 1.03 +0.01(0.98%)
Will RLYB be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RLYB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RLYB
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
RLYB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RLYB
Rallybio (RLYB) Gets a Buy from TD Cowen
Optimistic Buy Rating for Rallybio Amid Promising Developments in FNAIT Treatment
Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved
Rallybio's trial applications of RLYB212 in pregnant women with FNAIT approved
Rallybio participates in a conference call with JPMorgan